Key Segmentation
By Product
-
Cell Lines
-
Detection Kits
-
Cell Culture Reagents
-
Ligands
By Assay Type
-
cAMP Functional Assays
-
Calcium Functional Assays
-
β-Arrestin Functional Assays
-
Radioligand Binding and GTPγS Functional Assays
-
Internalization Assays
-
Trafficking Assays
By Application
-
Cancer Research
-
CNS Research
-
Metabolic Research
-
Cardiovascular Research
-
Inflammation Research
-
Respiratory Research
-
Others
By End-User
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutes
-
Contract Research Organizations
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
North America dominated the G-Protein Coupled Receptors (GPCRs) Market in 2025 with approximately 37.10% of global revenues, led by the United States' world-class pharmaceutical and biotechnology R&D ecosystem, exceptional academic GPCR research institutions, the presence of all major GPCR research tool suppliers' primary commercial operations, and the extraordinary commercial momentum of GLP-1 receptor-targeted therapeutics driving unprecedented investment in next-generation GPCR drug discovery programs.
Cancer Research dominated the market in 2025 with approximately 31.2% of revenues, driven by the extraordinary breadth of GPCR involvement in oncological processes including tumor proliferation signaling, angiogenesis, metastatic invasion facilitation, and tumor microenvironment immune modulation that collectively make GPCRs among the most multifaceted and attractive target classes in the rapidly expanding oncology drug discovery sector.
Cell Lines dominated the market in 2025 with approximately 46.1% of revenues, reflecting their foundational role as the essential biological substrate for every category of GPCR functional assay across pharmaceutical drug screening, receptor characterization, biased signaling quantification, and mechanistic pharmacology research conducted by pharmaceutical companies, CROs, and academic institutions globally.
The G-Protein Coupled Receptors (GPCRs) Market was valued at USD 4.14 billion in 2025.
The G-Protein Coupled Receptors (GPCRs) Market is expected to grow at a CAGR of 4.94% from 2026 to 2035.
Get in Touch
